Healthcare / BiotechnologyNasdaqCM
$1.42
-0.01 (-1.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-8.3M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
1012.5%
↑Gross Margin
N/A
•Debt/Equity
-0.53
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2014–2025 · 11 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-12.9M · FCF $-8.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Net Income | $-12.9M | $-12.9M | $-9.8M | $-9.3M | $-10.1M | $-9.4M | $-4.7M | $-2.2M | $-2.3M | $-234889.00 | $-29690.00 | $-15241.00 | $-15269.00 |
| EBITDA | $-12.6M | $-12.6M | $-9.8M | $-9.9M | $-10.1M | — | — | — | — | — | — | — | — |
| EPS | -37.56 | -37.56 | -54.90 | -56.52 | -64.08 | — | — | -394.20 | -496.80 | — | — | — | — |
| Balance Sheet | |||||||||||||
| Debt/Equity | -0.53 | -0.53 | 0.04 | 0.00 | 0.00 | — | — | — | — | — | — | — | — |
| Current Ratio | 1.79 | 1.79 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||
| Free Cash Flow | $-8.5M | $-8.5M | $-8.3M | $-8.2M | $-8.0M | — | — | — | — | — | — | — | — |
| Returns | |||||||||||||
| ROE | 1012.5% | 1012.5% | -343.9% | -79.0% | -52.0% | -34.6% | -120.1% | -39.8% | 1736.3% | -43.1% | 215.1% | -95.9% | -103.7% |
| Valuation | |||||||||||||
| P/B | — | — | 1.23 | 0.38 | 0.46 | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||
| EPS Growth | 31.6% | 31.6% | 2.9% | 11.8% | — | — | — | 20.7% | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-92.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-54.90 → -37.56
Residual
-92.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.